- Previous Close
0.5980 - Open
0.5561 - Bid --
- Ask --
- Day's Range
0.4633 - 0.6058 - 52 Week Range
0.3630 - 4.3689 - Volume
2,592,021 - Avg. Volume
1,129,039 - Market Cap (intraday)
1.515M - Beta (5Y Monthly) 1.10
- PE Ratio (TTM)
-- - EPS (TTM)
-8.7600 - Earnings Date Mar 18, 2025 - Mar 24, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.00
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. The company is also developing IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is based in Redwood City, California.
avinger.comRecent News: AVGR
View MorePerformance Overview: AVGR
Trailing total returns as of 3/31/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AVGR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AVGR
View MoreValuation Measures
Market Cap
1.52M
Enterprise Value
1.21M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.11
Price/Book (mrq)
0.39
Enterprise Value/Revenue
0.17
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-256.25%
Return on Assets (ttm)
-69.57%
Return on Equity (ttm)
-1,476.32%
Revenue (ttm)
7.26M
Net Income Avi to Common (ttm)
-17.35M
Diluted EPS (ttm)
-8.7600
Balance Sheet and Cash Flow
Total Cash (mrq)
5.9M
Total Debt/Equity (mrq)
144.39%
Levered Free Cash Flow (ttm)
-6.28M